Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent preventive treatment with dihydroartemisinin-piperaquine (IPT-DP). Arm 2: Intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) (IPT-SPAQ). Arm 3: Control - students will receive standard of care (no preventive treatment). Outcomes include P. falciparum infection and parasite density, anemia, cognitive function and educational testing, as well as infection prevalence and disease incidence in young children sleeping student's households to assess the impact on transmission.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 6 months
Healthy Volunteers: t
View:
• Currently enrolled in the study school
• Plan to attend the study school for the remainder of the school year
• Parent/guardian available to provide written informed consent
• Slept in the household for most nights in the last month
• Age 6-59 months
• Parent/guardian available to provide written informed consent
Locations
Other Locations
Malawi
Malaria Alert Centre
RECRUITING
Blantyre
Contact Information
Primary
Lauren M Cohee, MD MS
lauren.cohee@lstmed.ac.uk
00441513517674
Backup
Ruth van Zalinge
lstmgov@lastmed.ac.uk
00441517029396
Time Frame
Start Date:2024-10-14
Estimated Completion Date:2025-12
Participants
Target number of participants:1000
Treatments
Experimental: Intermittent Preventive Treatment with dihydroartemisinin-piperaquine (IPT-DP)
All students are treated at each intervention. Treatment will be with DP (females less than 13 years old and all males) or chloroquine (females 13 years old or older).
Experimental: Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine (IPT-SPAQ)
All students are treated at each intervention. Treatment will be with SP and AQ (females less than 13 years old and all males) or chloroquine (females 13 years old or older).